Lakefront Biotherapeutics NV current report, Q4 FY2016

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of November 2016. The filing serves to distribute a press release dated November 28, 2016, which is attached as Exhibit 99.1 and incorporated by reference.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document is a procedural filing to disseminate a press release rather than a financial statement.

Material Changes

No material financial changes or comparative period data are disclosed within the text of this filing. The content is limited to the announcement of the attached press release.

Guidance, Outlook, and Risks

The filing text does not contain management commentary, guidance, outlook, or specific risk factors. It notes that the information is incorporated by reference into Registration Statements on Forms F-3 and S-8.

Investor Verification Checklist

  • Verify the actual content of the press release attached as Exhibit 99.1, as the filing text itself contains no operational details.
  • Confirm the registrant name is Galapagos NV, noting a discrepancy with the provided metadata company name.
  • Review the referenced Registration Statements (File Nos. 333-211765, 333-204567, 333-208697, and 333-211834) for broader context.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.